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In 2008, an Integrative Oncology Program (IOP), aiming to improve patients’ quality of life during chemotherapy and advanced
cancer, was launched within the Clalit Health Organization’s oncology service at the Lin Medical Center, Haifa, Israel. The IOP
clinicalactivityisdocumentedusingaresearch-basedregistryprotocol.Inthisstudy,wepresentananalysisoftheregistryprotocol
of 15 Arab patients with cancer who were referred to the IOP. Analysis of patients’ reported outcomes using the Edmonton
Symptom Assessment Scale suggests that integrative medicine care improves fatigue (P = 0.024), nausea (P = 0.043), depression
(P = 0.012), anxiety (P = 0.044), appetite (P = 0.012), and general well-being (P = 0.031). Barriers to integration of traditional
and complementary medicine in supportive care of Arab patients are discussed followed by six practical recommendations aimed
at improving accessibility of patients to integrative supportive care, as well as compliance with treatments.
1.Introduction
The Middle East is represented by a rich spectrum of indige-
nous traditional schools of medicine modeled on a mosaic of
social, religious, and spiritual perspectives. Testaments to the
amalgam of indigenous roots of medical knowledge can be
found in current ethno botanical surveys which document
the use of herbs for cancer care in the regions of Israel [1],
Syria [2], and the Palestinian Authority [3]. In a survey
of Islamic and Jewish traditional medicine historical texts,
scholars from Israel, Egypt, and Turkey identiﬁed 44 herbs
associatedwithcancercare[4].Inasubsequentinternational
study,amultidisciplinaryteamofresearchersfromIsrael,the
Palestinian Authority, Jordan, Egypt, Morocco and Turkey
identiﬁed 143 articles on traditional/complementary med-
icine and cancer care that had been published on medline
in 12 Middle Eastern countries [5].
Several studies documented the signiﬁcant use of com-
plementary medicine (CM) by patients in the Middle East
during chemotherapy (Israel, 49%) [6] and radiotherapy
(Turkey, 44%) [7] and in subsets of patients with cancer:
pediatric (Lebanon, 15%; Turkey, 77%; Israel, 61%) [8–10],
gynecological (Turkey, 38%; Israel, 63%) [11, 12], and breast
cancer (Israel, 44%) [12].
In Israel, the concept of CM integration within conven-
tional care has been signiﬁcantly studied among the Arab
population in northern Israel. Ben-Arye and his colleagues
[13] have studied the prevalence of CM use and attitudes2 Evidence-Based Complementary and Alternative Medicine
toward its integration among 3840 patients in 7 primary care
clinics operated by Clalit Health Service (CHS) and found
that respondents in both groups signiﬁcantly supported CM
integration within primary care clinics.
Following this study, the Haifa and Western Galilee
District of CHS initiated a study in 2007 to examine the
possibility of CM integration within its oncology service
(OS). In 2008, an Integrative Oncology Program (IOP)
was launched as a free-of-charge clinical service aiming to
improve patients’ QOL during chemotherapy and advanced
disease state. The IOP is based on a multidisciplinary
team that includes physicians and practitioners that are
dual trained in conventional care as well as CM. The IOP
team provides a wide spectrum of traditional and CM
modalities which include nutritional counseling (diet and
supplements), herbal medicine, mind-body and touch ther-
apies, acupuncture, anthroposophic medicine, homeopathy
and spiritual care. In this paper, we present data regarding
Arab patients receiving integrative treatment oﬀered by the
IOP during the years 2009–2011. We examine the needs and
concerns of Arab patients who were referred to the IOP
and explore diﬃculties and barriers to the provision of CM
to this group of patients in integrative setting. Based on
these observations, we advocate practical recommendations
that may facilitate a cross-culturally sensitive approach that
will resonate with Arab patients’ expectations and needs in
similar integrative health settings.
2.MaterialsandMethods
2.1. Registry Protocol Data Collection. The IOP clinical activ-
ities are documented in a research-based registry protocol
(RP) approved by the IRB of the Carmel Medical Center,
Haifa, Israel. The RP monitors patients’ needs and concerns,
symptom and QOL assessment, and prospective evaluation
of clinical outcomes. In addition, the RP documents referral
patterns, CM practitioner-patient-oncologist communica-
tionaspects,andassessmentofthepatient’s,oncologist’s,and
the integrative physician’s perspectives regarding the impact
of the integrative intervention on the patient’s well-being.
Figure 1 illustrates the ﬂowchart beginning with the
patient’s referral to the IOP and concluding with follow-
up assessments of the integrative process. Referral to the
IOP may be initiated by the patient’s oncologist, oncology
nurse, or social worker and is limited to patients treated
within the oncology service during chemotherapy and/or
advanced cancer. Following the referral, an initial integrative
medical intake interview is scheduled for one hour with an
integrative physician (IP) who assesses the patient’s expec-
tations regarding CM, previous experience with traditional,
alternative or CM, as well as the patient’s narrative and
outlook regarding diagnosis, treatment, coping, and well-
being. The severity of symptoms, concerns, and expectations
are evaluated by the IP using the Edmonton Symptom
Assessment Scale (ESAS) and Measure Yourself Concerns
and Wellbeing (MYCAW) questionnaires and a detailed
bio-psychospiritual assessment. The session is typically
concluded with outlining of the treatment goals that are
shared by the patient and IP, followed by construction
of a preliminary treatment plan tailored to the patient’s
outlook (concerns, symptoms, willingness to experience
CM modalities, etc.) and level of evidence (eﬃcacy, safety,
possible interactions with chemotherapy, etc.). Each visit is
recorded by the IP in the patient’s medical ﬁle, and a clinical
summary is distributed to the patient’s healthcare providers
(oncologist, nurse, family practitioner, social worker, etc.).
Patients are typically scheduled for therapeutic integrative
medicine (IM) sessions that may include a variety of CM
modalities (e.g.,nutritional and herbal counseling, acupunc-
ture, mind-body, and manual therapies) provided from once
every week to once every 2-3 weeks. Prior to therapeutic
sessions, additional clinical assessment is conducted, aimed
to modify, if necessary, the treatment goals and plan.
Following 2–4 months of treatment, a concluding clinical
assessment is performed with the use of ESAS and MYCAW
questionnaires. More therapeutic sessions are provided, if
deemed necessary, for patients with advanced cancer or for
those receiving adjuvant chemotherapy. Such sessions are
also regularly monitored. Figure 1 illustrates supplemental
evaluation documented within the registry protocol regard-
ing themes of patients’ expectations and communication
with healthcare providers. Follow-up evaluations include
a self-administered questionnaire completed by the IP at
the conclusion of the ﬁrst medical intake, semistructured
telephone interviews with patients conducted by a researcher
following the ﬁrst intake and after the concluding clinical
evaluation and a questionnaire administered to the patient’s
oncologist following the concluding evaluation. In this eval-
uation process, the patient’s and clinician’s perspectives are
independentlycomparedregardingexpectations,satisfaction
with treatment and communication, as well as needs that
were not fully addressed.
2.2. Assessment Methods. Assessment questionnaires include
the following.
(a) MYCAW is an individualized questionnaire con-
structed and validated by Paterson et al. [14] for evaluating
outcomes in cancer support care that includes complemen-
tarytherapies[15].Participantswereaskedtoenumerateone
or two concerns and, using a seven-point scale, to score these
concerns and their general feeling of well being. The follow-
up questionnaire also includes the following open question:
“Reﬂecting on your time with this Centre, what were the
most important aspects for you?”
(b) ESAS is a questionnaire developed for assessing the
symptoms of patients receiving palliative care [16], as well
as for assessing outcomes in an integrative oncology context
[17].Itconsistsofan11-pointnumericalratingscaleforself-
reporting of nine common symptoms of cancer, with a 10th
scale for assessing the feeling of well-being. Both MYCAW
and ESAS questionnaires were linguistically validated to
Hebrew using bidirectional translation from their English
origin to Hebrew and vice versa.
(c) Questionnaires administered to the IP and/or oncol-
ogist and/or patients were developed by the authors fol-
lowing a comprehensive literature review of patients’ needs,
concerns, and expectations regarding CM in the oncology
setting and interviews with 24 patients in diﬀerent phasesEvidence-Based Complementary and Alternative Medicine 3
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Figure 1: Flowchart of clinical and communicational evaluation along the sequence of integrative sessions within the Integrative Oncology
Program (IOS: integrative oncology service; IP: integrative physician; IM: integrative medicine).
of oncology treatment and with 61 health care providers
(HCPs) and CM practitioners. Afterwards, a focus group,
composed of 5 patients in diﬀerent phases of cancer treat-
ment, was used to reﬁne the questionnaire and improve its
comprehensibility. The focus group participants varied in
age, sex, education, health status and CM use. Based on
their feedback, the questionnaire was revised and sent for
reappraisal to 7 of the HCPs. The ﬁnal version of the 20-
question questionnaire was administered by the IP following
initial consultations. The questionnaire consists of 9 limited-
choice questions (yes, no, other, or not relevant), 4 multiple-
choice questions, one open question, and 6 questions that
use a Likert-like scale. Independent researchers interviewed
patients,followingtheIP’sinitialandconcludingassessment,
usingasimilarformofthequestionnaireﬁlledinbytheIP.In
addition, a researcher typically phoned to interview patients
no longer attending the IM sessions. Another questionnaire
was administered to the patient’s oncologist following the
IP’s concluding assessment. This shortened questionnaire
format consists of 4 questions including 3 that utilize a
Likert-like scale.
Data was evaluated using the SPSS software program
(version 18; SPSS Inc., Chicago, Ill). Wilcoxon Signed
Ranks Test and paired t-test were used to detect diﬀerences
before and after the treatment scores in MYCAW and ESAS
questionnaires.
3. Results and Discussion
Participation in the registry protocol-based IOP research was
limited to patients in the CHS Haifa and Western Galilee
OS during chemotherapy or advanced active disease. The
total number of new patients referred to the OS ranges
from 800 to 1000 per year. Data regarding the cultural and
religious characterization of this newly referred population
was not available, nor was data related to the population
of patients who theoretically meet the inclusion criteria for
referral to the IOP. The best culture-related data available
was obtained from analysis of nurse oncology intakes (NOI)
which were performed prior to beginning chemotherapy
in patients receiving intravenous adjuvant, neoadjuvant, or
palliative chemotherapy for the ﬁrst time in their life. The
NOI-based data was collected and analyzed starting from
14/7/2009 (parallel to the launching of the registry protocol)
and up to 14/7/2011.
Based on the patient’s self-report of spoken language
during the NOI, we divided patients into two groups: Arabs
(patients speaking Arabic solely or in addition to Hebrew or
other languages) or non-Arabs (patients speaking Hebrew
or other languages but not Arabic). In cases not determined
by the language criterion, we assigned the patient to one of
these groups according to the father’s name. Five hundred
thirty-one patients were thus grouped based on the NOI4 Evidence-Based Complementary and Alternative Medicine
data during the two-year study, of whom 103 were Arabs
(19.4%) and 428 non-Arabs (80.6%). This data may not
reﬂect the entire population of patients who could have
been referred potentially by the OS health providers to the
IOP, for the following reasons: (a) patients with recurrent
disease treated with chemotherapy initiated prior to July
2009 (about 42.4% of patients in the OS are receiving
chemotherapy for recurrent disease); (b) patients receiving
oral chemotherapy, biological or hormonal therapy; (c)
patients receiving palliative care with no chemotherapy
initiated after July 2007.
During this two-year period, 230 of the 531 patients
(recorded in NOI data) were referred to the IOP by the
OS oncologists, oncology nurses, or OS social workers.
Of these referrals, 224 met the inclusion criteria for IOP
admission and enrollment in the registry protocol-based
research. Of the 224 patients invited for IOP assessment,
203 (response rate 90.6%) participated in the IP’s initial
intake and provided written consent to participate in the
research protocol study. Of the 203 study subjects, who were
monitored in the registry protocol, 15 were Arabs (7.39%)
and 188 were non-Arabs (92.61%). Figure 2 illustrates an
algorithm of the study’s recruitment and illustrates the
proportion of Arab versus non-Arab patients along the
funnel leading to the registry protocol tracking.
Of the 21 patients who were referred to the IOP but
did not attend the IP’s intake, 4 were Arabs and 17 non-
Arabs. The main reason for nonattendance was diﬃculty in
scheduling appointments during progressive treatment.
3.1. Registry Protocol Demographics of Arab Patients. The
demographic characteristics of Arab patients enrolled in the
integrative registry protocol within the OS are presented
in Table 1. This population is characterized by female
predominance (11/15, 73.3%), mean age of 52.4 years (range
22–77), and variety of religions (6 Muslim, 5 Christian,
and 4 Druze). Most patients reside in cities (9 urban, 4
rural, and 2 semiurban) which are often very far from the
OS located in Haifa (4 patients live in zone 1 (Haifa), 1
patient in zone 2 (up to 20km from Haifa), and 10 in
zone 3 (>20km from Haifa)). Of the 15 patients, 9 were
diagnosed with localized disease and were receiving adjuvant
chemotherapy following surgery and 6 had advanced disease
and were receiving palliative chemotherapy. Patients’ cancer
sites included the following: breast (6), colon (3), stomach
(1),lung(1),bladder(1),testicles(1),mesothelioma(1),and
an undiagnosed site (1).
3.2. Assessment of Referral, Expectations, and Communica-
tion during and following IP Intake. Referral to IOP was
performed via health care practitioners’ (HCPs) structured
referral letters that specify the indications for referral to the
integrative treatment. Of the 15 referrals, 9 were adminis-
tered by oncology nurses, 4 by oncologists, and 3 by the OS
social workers (one referral was administered by both nurse
and social worker).
Nine of the 15 patients (60%) reported previous use
of traditional/CM in the context of cancer care. Although
the IP speciﬁcally inquired about cancer-related CM use
at the beginning of the medical intake, the majority of
patients disclosed CM use only when asked for the second
or third time towards the end of the interview. In these cases,
disclosure was often related to the patient becoming aware
that the deﬁnition of cancer-related CM also includes QOL
improvement and symptom management rather than curing
cancer.
General expectation to reduce chemotherapy side eﬀects
was the leading referral indication (6 referrals), followed
by more speciﬁc expectations concerning symptoms such
as anxiety (5), fatigue (3), and vomiting (2). Compared
to indications for referrals, patients expressed additional
expectations from the IP: what to eat and which herbs to use
(4), how to alleviate fatigue and strengthen their condition
(4), and how to improve management of pain (3), emotional
state (2), and other symptoms. Expectation analysis of each
of the 15 referrer-patient couples revealed that matching
of expectations was largely evident in only four pairs for
speciﬁc symptoms that need to be addressed by the IP
(e.g., improving urination, bitter taste, stomatitis, and other
gastrointestinal symptoms). Compared to HCPs, patients
expressed more concrete expectations from the IP (e.g.,
speciﬁc symptom improvement versus general reduction of
side eﬀects) and in some cases anticipated outcomes beyond
QOL improvement such as cancer cure and recurrence
prevention.
AssessmentofHCP-IPcommunicationfollowingtheIP’s
initial intake revealed that the IP addressed a medical letter
to all 15 patients’ oncologists and to 14 nurses, 14 social
workers, and 9 family physicians. Typically, these letters were
referred to 3-4 of the patient’s HCPs and often responded to
by at least two HCPs.
Patient’s and IP’s evaluation were based on question-
naires completed by the IP following the initial visits and
semistructured interviews with patients that were conducted
byanindependentresearcher.Ofthe15patientsinterviewed,
5 anticipated diﬃculty in implementing the therapeutic plan
as presented by the IP in the ﬁrst visit. In contrast, the
IP expected diﬃculty in 12 of the patients, mainly due to
limitedaccessibilitytotheclinicandanimpressionthatthese
patientsdoubtedthebeneﬁtsofthetreatment.In12outof15
patients there was incongruence between the patient and IP
regarding perceived diﬃculty in implementing the treatment
plan. This patient-IP mismatch is also evident in 9 patients
regarding satisfaction following the initial visit. Compared
to patient evaluations, IP scores were higher in 7 of these 9
pairs.
3.3.ClinicalAssessmentinInitialIPIntakes. Evaluationofthe
severity of patients’ two main concerns was performed both
in the initial IP intake and the concluding session that fol-
lowed several therapeutic sessions. This evaluation wasbased
on the MYCAW questionnaire which followed symptom
assessment based on the ESAS questionnaire and an open
interviewwiththeIP.Leadingconcernsconsistedofgastroin-
testinal symptoms (9) including nausea/vomiting, digestion,
bitter taste, and other mouth symptoms; emotional distressEvidence-Based Complementary and Alternative Medicine 5
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Figure 2: Algorithm of study recruitment (in brackets the proportion of Arab patients).
Table 1: Demographic characteristics of Arab patients enrolled in the integrative registry protocol within the oncology service (OS) in the
Lin Medical Center, Haifa.
Patient’s code Age Gender Religion Settlement type and zone∗ Cancer site Oncology status (and chemotherapy setting)
1 59 F Christian Urban 1 Breast Localized (adjuvant)
2 44 F Muslim Urban 3 Breast Localized (adjuvant)
3 62 F Christian Urban 3 Breast Advanced (palliative)
4 47 M Druze Rural 3 Mesothelioma Advanced (palliative)
5 46 F Druze Rural 3 Stomach Localized (adjuvant)
6 45 F Druze Rural 3 Breast Localized (adjuvant)
7 44 F Druze Semiurban 3 Unknown Advanced (palliative)
8 62 F Christian Urban 3 Breast Localized (adjuvant)
9 38 F Muslim Urban 3 Breast Localized (adjuvant)
10 22 M Muslim Rural 3 Testicular Localized (adjuvant)
11 65 F Muslim Urban 3 Bladder Localized (adjuvant)
12 67 M Muslim Urban 1 Colon Localized (adjuvant)
13 67 F Muslim Semiurban 2 Lung Advanced (palliative)
14 42 F Christian Urban 1 Colon Advanced (palliative)
15 77 M Christian Urban 1 Colon Advanced (palliative)
∗Distance from the oncology service in Haifa is classiﬁed according to zones as follows: zone 1: city of Haifa; zone 2: up to 20 kilometers from Haifa; zone3 :
more than 20 kilometers from Haifa.
(5); fatigue (5); pain/neuropathy (3); other symptoms. The
average degree of concern on a 7-point scale (from 0: not
bothering me at all to 6: bothers me greatly) is 5.16.
At the conclusion of every initial intake, the IP and
the patient deﬁned the integrative medicine treatment goals
together. This shared decision-making was regarded by the
IP as the climax of the meeting that determined which
objectives were both acknowledged and accepted by the
patient and could be fully regarded in the formulation of
the treatment plan that followed. Common treatment goals
accepted by both the patient and the IP in the 15 intakes are
as follows: fatigue (12), pain (12—including neuropathy and
headache), emotional distress (8—including also the care-
giver’s well-being), nausea/vomiting (8) and other gastro-
intestinal symptoms (constipation-3, taste alteration (3),
mouth sores (1), diarrhea (1), and heartburn (1)), appetite
loss (5), diﬃculty in breathing (4), sleep (4), and others
(miscellaneous).
3.4. Clinical Outcome Assessment. The number of integrative
medicine sessions that followed the initial IP intake up to the
concluding session varied from 1 (two patients participated
only in IP intakes and did not attend further sessions) to
39 (mean 9.06, median 8). In total, 136 integrative medicine6 Evidence-Based Complementary and Alternative Medicine
sessions have been recorded in the registry protocol for these
patients. Typically, various CM modalities were integrated
in each of the sessions and were coded according to the
main CM modality and its speciﬁc technique within this
modality (e.g., guided imagery is regarded as CM code
within mind-body modality). Altogether, 383CM codes
were recorded during the 136 sessions. CM modalities that
were practiced include acupuncture (in 13 patients), herbal
medicine mainly traditional Arab herbs (12), manual and
touch therapies (10 including acupressure, Reiki, and shi-
atsu), nutritional counseling with traditional Arab medicine
orientation (9), mind-body-spiritual practices (7 including
breathing exercises, guided imagery, and spiritual counseling
and meditation), nutritional supplements (5), homeopathy
(2), exercise counseling (2), and anthroposophic medicine
(1).
Clinical outcome assessment was mainly based on IP’s
and patient’s evaluation performed during the concluding
session. Following this session, the IP asked the oncologist to
assess the integrative treatment role in the patient’s care, thus
adding a third perspective to the concluding evaluation. The
extent to which clinical assessment was achieved was graded
on three levels: comprehensive—in 8 of 15 patients a 3-way
perspective (IP’s, patient’s, and oncologist’s) evaluation was
obtained; partial—for 3 patients, evaluation was available
from 2 of the 3 assessors; deﬁcient—4 patients had no,
or almost no, evaluation at all. These three levels of
assessment comprehensiveness was often correlated with the
IP’s evaluation of patient’s compliance (high, moderate, and
low).
Analysis of pre- and posttreatment outcomes was per-
formed by comparing baseline and concluding session scores
on the MYCAW and ESAS questionnaires. MYCAW scores
which reﬂect patients’ leading concerns, improved from
5.15 ± 0.933 to 2.05 ± 1.504 (P<0.0001) (mean ± SD on
a 7-point scale ranging from 0: not bothering me at all to
6: bothers me greatly). MYCAW’s well being score improved
from 4 ± 1.155 to 1.9 ± 1.853 (P = 0.015). In addition,
the following symptoms improved as reﬂected by comparing
pre- and post-ESAS scores (11-point scale ranging from 0
to 10): fatigue (6.1 ± 2.514 versus 2.9 ± 2.47, P = 0.024),
nausea(3.9±2.998versus1.7±2.669, P = 0.043), depression
(4.4±2.951versus1.1±1.595,P = 0.012),anxiety(3.6±3.893
versus 1.3 ± 2.058, P = 0.044), appetite (4.7 ± 3.466 versus
0.9±1.729, P = 0.012), and feeling of well-being (5.9±2.601
versus 3.3 ± 2.869, P = 0.031). No signiﬁcant statistical
diﬀerenceswerenotedregardingtheESASsubscalesforpain,
drowsiness, shortness of breath, and sleep quality.
Within the group of 8 patients (coded in Table 1 as
patients 4–6, 8-9, 11-12, 15) with comprehensive assessment
andhighcompliance,MYCAWscoresreﬂectedimprovement
in regard to nausea/vomiting (4 patients), fatigue (3), and
emotional distress (3). Improvement in ESAS scores was
more evident for pain (6), fatigue (6), nausea (5), anxiety
(5), and depression (4). Patients’ narrative evaluation as
obtained in the MYCAW questionnaire administered in
the concluding session emphasized the following themes:
(a) improved acceptance of natural remedies (e.g., patient
4: “I feel better with natural remedies”); (b) a sense of
well-being and empowerment (e.g., patient 5: “Following
acupuncture I feel stronger”; patient 11: “Treatment with
needles and breathing exercises gave me more strength...
more energy”); (c) increased symptom control (reported
by all 8 patients); (d) calming eﬀect of the treatment (e.g.,
patient 6: “Acupuncture relieved pain and calmed me”;
patient 12: “Acupuncture releases the body and reduces
agitation”).
Within the group with deﬁcient assessment and low
c o m p l i a n c e( 4p a t i e n t sc o d e da s1 ,2 ,7 ,a n d1 4 ) ,t w oo f
the patients attended only one session (IP intake), whereas
the other two attended 2 to 3 sessions. The information
regarding the noncompliance of this group of patients is
indirect and based on either a telephone interview with
the independent researcher following the initial IP intake
(patient 4 reporting reluctance towards needle insertion) or
interviews with the patients’ oncology nurse (e.g., patient 7:
“Although the patient had faith in CM, she was frustrated by
the dramatic deterioration in her health and felt that neither
chemotherapy nor CM improved her condition”; patient 14:
“The patient ignored the severity of her illness. It seems
that QOL is not the most important theme for her; she just
wished to “taste” CM but not make full use of it”).
Last but not least, the group of 3 patients with partial
assessmentandmoderatetohighcompliance(patientscoded
as 3, 10, and 13) may add insight to the perceptions of the
other two groups. The number of integrative sessions in
this group ranged from 8 to 16 per patient. In contrast to
the deﬁcient assessment group, evaluation was available but
incomplete. With two of the patients, clinical improvement
was either implicit (patient 3 reporting sleep improvement
following acupuncture) or explicit (patient 13 reporting that
“following needling I felt better in breathing and returned a
diﬀerent person”). In contrast, clinical evaluation of patient
10 is contradictory, as evident in the simultaneous improve-
ment and worsening in MYCAW and ESAS symptoms and
the low score in the oncologist’s evaluation.
3.5. Discussion. In this study, we present our experience with
Arab patients referred to the IOP with the aim of improving
their well-being during chemotherapy for either localized
or advanced cancer. The main question we encounter daily
is how optimal our communicational and clinical approach
is in meeting the needs of Arab patients with cancer who
are being treated in the IOP. Our intention was not to
compare such aspects between Arab and Jewish patients
but rather to understand and acknowledge cross-cultural
barriers that potentially hamper optimal integrative care.
The hypothesis that potential barriers do exist in provision
of complementary therapies among the Arab population was
recently supported by Keshet and Ben-Arye who surveyed
58 HMO-related complementary medicine clinics in north
Israel [18].
In our study, we cautiously suggest that a disturbing gap
exists between the percentage of Arab patients referred to
nurseoncologyintakes(19.4%)andthosereferredultimately
to the IOP (only 7.4% were ﬁnally enrolled in the registry
protocol), as compared to non-Arab patients.Evidence-Based Complementary and Alternative Medicine 7
Table 2:PotentialbarrierstoCMintegrationinsupportivecancercareofArabpatientsinnorthernIsraelandrecommendationsforbridging
the barriers.
Potential Barrier Recommendation Practical implications
Geographical factor: 68% of the
Arab patients receiving
chemotherapy reside >20km from
the IOP in Haifa OS
Opening a second site of IOP
activity in Haifa periphery (zone 2
or 3)
Minimizing distance-bias may help patients to overcome
initial hesitations regarding the ﬁrst IP visit and enable
them to attend weekly CM sessions
Not having an Arab CM
practitioner in the IOP staﬀ
Inclusion of an Arab CM
practitioner (preferably a dual
practitioner) in the IOP
Improving verbal communication with patients,
enhancing the IOP attentiveness to their needs, and
concerns and promoting development of traditional
Arab-oriented therapies
Gap between patients’ expectations
and IOP objectives and CM
repertoire
Increasing IP awareness of patients’
expectations; developing integrative
modalities that will resonate more
with traditional Arab medicine
Matching patients’ expectations with IP goals of treatment
is essential and should be continuously monitored,
especially with regard to QOL-oriented care rather than
“attacking” cancer cells
Suboptimal matching of CM
modalities to patients’ cultural and
religious codes and beliefs
Raising the IP’s and CM
practitioner’s awareness of cultural
and religious codes within the Arab
society
The IOP staﬀ need to consider cultural appropriateness of
certain CM modalities (e.g., touch), reluctance concerning
unfamiliar treatments (e.g., acupuncture, guided
imagery), and gender issues (patient treated by a CM
practitioner of the opposite sex, presence of another
person in the room, etc.)
Suboptimal communication
between the IOP and the other OS
sectors
Improving IP-oncologist-nurse-
social worker communication in
order to enhance coordinated
comprehensive care
Closer monitoring of patient compliance may also reveal
the patient’s diﬃculties and barriers to seeking integrative
care
Lack of communication with the
patient’s family physician (FP)
Initiating a structured form of
communication with the patient’s
FP via summary letter e-mailed
from the patient’s medical ﬁle
The FP often operates within the cultural milieu of the
patients, care givers, and the extended family circle
Integrative care-oriented medical education courses are
needed to familiarize FPs with the IOP activity
Although the NOI data includes only i.v. chemotherapy-
naivepatientsanddoesnotnecessarilyreﬂectpatientstreated
with oral chemotherapy or for recurrent disease or in a
palliative context, the gap between the 103 Arab patients
admitted to NOI in the 2-year period and the small group of
15 patients actually enrolled in the registry protocol neces-
sitates further contemplation. What are the reasons for this
referral bias? Although further studies are needed to answer
this query, four explanatory factors may be hypothesized:
(1) patient-related factors (e.g., lack of patient’s interest
or belief that CM is beneﬁcial during chemotherapy); (2)
culturally-dependent factors (e.g., health-belief model that
views cancer treatment in the context of “cure” and survival
extension, rather than focusing on QOL aspects); (3) HCP-
relatedfactors(e.g.,OShealthprovidersspeculatingthatCM
may be less appropriate for Arab patients); (4) HMO-related
factors (e.g., limited access of Arab patients that live in zone
3, far from Haifa, to the IOP; lack of Arab HCPs within
the OS and the IOP staﬀ, which limits communication and
complicates matching expectations regarding CM).
The question of barriers in providing integrative care
to Arab patients is multifaceted (Table 2). We initiated the
registry protocol and gained a preliminary unsatisfactory
experience with the ﬁrst 3 Arab patients (coded 1–3). As
we gained more experience, we acknowledged that goodwill,
openness, and sympathy to the needs of the Arab patient are
not suﬃcient to catalyze a breakthrough. The tipping point
was established when we understood that a cross-cultural
dialogue needs at least two partners to embark on a journey.
We understood that the IP-patient interaction mirrors a
more complex cultural interaction between individual- and
collective-oriented perspectives. On a practical level, we
learned that patients may view CM modalities not only by
an eﬃcacy-safety scale (e.g., Does it work? Is it safe?) but
also as metaphors and gestures (e.g., the invasiveness of the
acupuncture needle or the calmness and feeling of content-
ment induced by touch). Thus, our experience has taught us
that we need our patients to discover their needs alongside
our own bias. Furthermore, we learned how patient-tailored
treatment necessitates both skill and modesty to determine
the appropriateness and sequence of treatment with herbs,
touch, breathing, or needles. The establishment of trust
between the patient and the IP/CM practitioner is the key
element in modeling the therapeutic plan. Barriers such
as the patient’s reluctance to experience unfamiliar CM
modalities (e.g., acupuncture, massage, and guided imagery)
should not be ruled out in advance but perhaps could
determine the sequence of CM modalities suggested along
the course of treatment. As we gained more experience
with Arab patients, we learned that herbal and nutritional
counseling should typically be prioritized as the ﬁrst CM
modality of choice, which then can facilitate trust and
openness towards additional modalities. Moreover, within
each CM modality we were able to identify a scale of tech-
niques ranging from “acceptable” to “odd” (e.g., within the
mind-body modality, we typically started with a breathing8 Evidence-Based Complementary and Alternative Medicine
exercise, moving gradually, in following sessions, to suggest
closing the eyes, guided imagery, deeper meditation, etc.).
Gender is another trust-dependent factor that may hamper
patients’ willingness to experience CM, which includes the
following considerations: a mismatch of patient’s and IP/CM
practitioner’s gender (typically female patient and male IP),
the presence of another person in the room from the same or
opposite sex (such as the patient’s spouse, relative or another
CM practitioner), and immodesty as a challenge determined
either by the CM procedure (e.g., acupuncture in the knee
area)orthepatient’scultural/religiousvalues,orboth.Asour
clinical and communicational skills developed, we learned
to acknowledge the complex of cultural considerations,
discover our own limitations in understanding “the other”
and “ourselves” in the cross-cultural equation, and become
increasingly committed to the needs, concerns, and hopes of
our patients who speak Arabic, Hebrew, and the many other
languages spoken in our region’s contemporary “Tower of
Babel”.
3.6. Recommendations and Practice Implications. We support
the following recommendations (see Table 2)a i m e da t
improving accessibility and motivation of Arab patients to
seek integrative supportive care in our oncology service. We
believe that these recommendations may also be beneﬁcial in
other integrative settings in the West that provide supportive
cancer care to patients from cultural minorities.
(1) Location and accessibility of the integrative oncology
center is a pivotal aspect, and therefore, IOP should
be operated geographically within the minority pop-
ulation.
(2) The integrative medicine staﬀ should include a CM
practitioner from the cultural minority in order
to identify patients’ cultural-related expectations,
concerns, and barriers, with the aim of bridging
the gap between traditional, complementary, and
conventional agendas regarding cancer supportive
care.
(3) Developing integrative modalities that will resonate
more with traditional medicine especially regarding
theuseofherbsandnutritioninrelievingchemother-
apy side eﬀects and improving QOL.
(4) Raising IPs’ and CM practitioners’ awareness of the
patient’s cultural and religious codes and beliefs
(e.g., appropriateness of applying manual therapies
(including massage and acupuncture) that may be
interpreted by patients as immodest).
(5) Close monitoring of the patient’s compliance by
improving IP-oncologist-nurse-social worker com-
munication regarding the patient’s diﬃculties and
barriers to receiving thorough integrative care.
(6) Initiating structured communication with the pa-
tient’s family physician, who often operates within
theculturalmilieuofthepatients,caregivers,andthe
extended family circle.
3.7. Study Limitations and Recommendations for Following
Studies. This study is limited by several considerations that
may restrict the generalization of our ﬁndings to other
societies and clinical settings. The group of 15 Arab patients
inourregistryprotocolissmallandlacksacontrolgroupnot
receiving integrative care. Thus, clinical outcomes reported
in this paper may not strictly reﬂect the speciﬁc eﬀects of
CM intervention but also the complex interactions among
the following factors: natural history of the disease and
treatment-related eﬀects (improvement as well as deterio-
ration caused by chemotherapy) on patients’ quality of life,
clinical natural history (e.g., improvement of surgery-related
symptoms along the course of time, disease progression
causing QOL worsening, etc.), anxiety relief following the
patient’s adjustment to treatment, and nonspeciﬁc eﬀects
of his/her interaction with the IP and CM practitioners
(e.g., attention, empathy, professionalism, etc.). However,
taking this limitation into account, the comprehensiveness
of our methodology provides us with a perspective of real-
life patient-tailored settings and the ability to interpret
social, cultural, and clinical ﬁndings in a broad and complex
context, though the researcher’s subjectivity should be kept
in mind as potential bias. Another limitation is the lack of
dataregardingArabpatientswithrecurrentdiseaseorduring
palliative care who potentially could have been referred to
the IOP. Missing data is also a limiting aspect concerning the
registry protocol patients with low compliance. The current
study lacks suﬃcient qualitative research that could shed
light on the motives of those Arab patients who discontinue
treatment or, on the other hand, those who were highly
compliant. Finally, this study is limited to the local features
of the Arab community in northern Israel and the local
characteristics of the CHS oncology service in Haifa, and the
Integrative Oncology Program operated within the OS.
4. Conclusions
Barriers to integration of CM in the supportive care of
Arab patients in northern Israel are multifaceted and include
cross-cultural and institutional factors that inﬂuence referral
and contribute to compliance and clinical outcomes. Bridg-
ing cultural gaps and traditional values with regard to CM
can assuage patients’ concerns and, ultimately, facilitate an
enhanced integrative approach to symptom control resulting
in improved quality of life.
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